Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update

Poised to transition SPR994 from Phase 1 to Phase 3 around year-end 2018 CAMBRIDGE, Mass. , April 02, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics , Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for


Leave a Reply

Your email address will not be published.